Prosecution Insights
Last updated: April 19, 2026

Abelzeta Inc.

4 pending office actions

Portfolio Summary

4
Total Pending OAs
1
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18183681 Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof OUSPENSKI, ILIA I 1644 Non-Final OA Mar 14, 2023
18044263 METHODS FOR LYSING BACTERIAL CELLS FERNANDEZ, SUSAN EMILY 1651 Final Rejection Mar 07, 2023
18173187 CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF KELLY, ROBERT M 1638 Non-Final OA Feb 23, 2023
17911524 COMBINED CHIMERIC ANTIGEN RECEPTOR TARGETING CD19 AND CD20 AND APPLICATIONS THEREOF DUFFY, PATRICIA ANN 1645 Non-Final OA Sep 14, 2022

Managing Abelzeta Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month